Indication

CINCA syndrome

**CINCA syndrome** (chronic infantile neurological cutaneous and articular syndrome), also designated as neonatal-onset multisystem inflammatory disease (NOMID), is a rare, severe autoinflammatory disorder that represents the most debilitating form of cryopyrin-associated periodic syndromes (CAPS). Read more about CINCA syndrome

0 drugs 0 manufacturers

Advertisement

Drugs that treat it

Common CINCA syndrome therapies.

0 drugs

No drugs are available

This indication does not currently contain public drugs.

Filter & compare in the drug finder →Opens the drug finder with CINCA syndrome preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About CINCA syndrome.

**CINCA syndrome** (chronic infantile neurological cutaneous and articular syndrome), also designated as neonatal-onset multisystem inflammatory disease (NOMID), is a rare, severe autoinflammatory disorder that represents the most debilitating form of cryopyrin-associated periodic syndromes (CAPS).

Predominantly presenting in neonates or early infancy, the condition is driven by gain-of-function mutations—either germline or somatic mosaicism—in the *NLRP3* gene, which causes hyperactivation of the NLRP3 inflammasome and uncontrolled overproduction of interleukin-1 beta (IL-1ß).

It is clinically characterized by a classic triad consisting of a migratory, non-pruritic urticaria-like rash; central nervous system manifestations such as chronic aseptic meningitis, sensorineural hearing loss, and papilledema; and progressive, severe arthropathy characterized by abnormal epiphyseal bony overgrowth.

Personalize your experience

Follow CINCA syndrome and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it